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Several viruses in the Arenavirus genus of the family Arenaviridae cause severe, often fatal, hemorrhagic fever. One such virus, Lassa
virus (LV), is a frequent cause of disease in Africa, and survivors often are left with substantial neurological impairment. The feasibility of
protective immunization against LV infection, and the associated disease, has been demonstrated in animal models, using recombinant
vaccinia viruses to deliver Lassa proteins. Circumstantial evidence implicates cellular immunity in this Lassa-induced protection, but this has
not been confirmed. Here, we describe DNA vaccines that encode LV proteins. A single inoculation of a plasmid encoding full-length Lassa
nucleoprotein (LNP) can induce CD8+ T cell responses in mice and can protect against challenge with two arenaviruses, lymphocytic
choriomeningitis virus (LCMV) and Pichinde virus (PV). A DNA minigene vaccine encoding a 9 amino acid sequence from LNP also
induces CD8+ T cells and protects against arenavirus challenge, thus confirming prior speculation that protective cellular immunity is induced
by LV proteins.
D 2005 Elsevier Inc. All rights reserved.
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Several viruses in the family Arenaviridae cause severe,
and often fatal, hemorrhagic fevers in humans and, in
consequence, are members of the category A group of the
NIAID priority pathogens list (http://www2.niaid.nih.gov/
biodefense/bandc_priority.htm). All family members belong
to a single genus, Arenavirus, and are sub-divided into two
groups on the basis of serological data. Viruses in the first
group are indigenous to the Americas and are termed New
World arenaviruses. The second group, the Old World
arenaviruses, originated in Africa and includes the proto-
typical arenavirus lymphocytic choriomeningitis virus
(LCMV) and Lassa virus (LV). LV is endemic in West
Africa, and causes Lassa fever, a devastating disease which0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.01.019
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(reviewed, McCormick and Fisher-Hoch, 2002). Although
the antiviral drug ribavirin is beneficial in limiting the
morbidity and mortality caused by LV, especially if
administered relatively early in infection (McCormick et
al., 1986), the disease is fatal in ~2–16% of cases, and
survivors often have significant sequelae, such as sensor-
ineural deafness (Cummins et al., 1990). Despite the large
toll of human morbidity and mortality, and the perceived
threat posed by bioterrorist use of this virus, no approved
vaccine is available to counter this infection.
Vaccination against Lassa fever is an achievable goal.
Two of the four viral proteins – the nucleoprotein (NP) and
glycoprotein (GP) – can confer protection against LV
challenge. Early work using guinea pigs showed that the
Lassa NP, expressed from a recombinant vaccinia virus,
conferred protection (Clegg and Lloyd, 1987), and subse-
quent studies confirmed these data, and also showed that
vaccinia-expressed Lassa GP could protect (Morrison et al.,005) 87–98
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immunity induced by LV sequences has not been limited to
guinea pigs. More than a decade ago, it was shown that
primates (rhesus macaques) immunized with recombinant
vaccinia expressing the Lassa GP were protected against a
normally lethal LV challenge (Fisher-Hoch et al., 1989), and
a subsequent extensive study of recombinant vaccinia virus
immunizations in rhesus and cynomolgus macaques showed
that the Lassa GP, but not the Lassa NP, conferred protection
(Fisher-Hoch et al., 2000). These studies provide compel-
ling evidence that vaccination against Lassa fever is
possible, but the protective immunological component
induced by the LV vaccines has not been positively
identified. Lassa-specific antibodies may not be responsible:
they could not be detected in protected guinea pigs, and the
primate studies found no correlation between vaccine-
induced antibodies and protection. Furthermore, a killed
LV vaccine that induced antibodies in rhesus macaques
failed to protect against virus challenge (McCormick et al.,
1992). Thus, by a process of exclusion, the data suggest that
the protection induced by LV vaccines relies on the cellular
immune response. If true, this would be consistent with our
knowledge of immunity to the related arenavirus, LCMV.
CD8+ T cells play a key role in controlling primary LCMV
infection, and a vaccine that induces only CD8+ T cells, in
the absence of any virus-specific antibodies, confers
complete protection against a normally lethal LCMV
challenge (Klavinskis et al., 1989; Whitton et al., 1993).
The main goal of the present study was to determine the
nature of the protective immune response induced by LV
proteins. We approached this issue by (i) determining if
DNAvaccines encoding LV proteins could confer protection
against subsequent arenavirus challenge; (ii) identifying
potential immunogenic epitopes within LV; (iii) assessing
their immunogenicity in vivo; (iv) demonstrating that an
isolated CD8+ T cell epitope from LNP could confer
protection, thereby positively identifying the immunological
mechanism that underlies the protective immunity induced
by Lassa proteins. In addition, we have (v) examined the
possibility that Old World and New World arenaviruses may
share sequences capable of inducing cross-protective
immune responses.Fig. 1. pLNP expresses the Lassa virus nucleoprotein. HeLa cells were transfect
Materials and methods. Fluorescent cells were visualized using a Nikon AxiophoResults
DNA vaccines encoding full-length LV nucleoprotein:
protective efficacy against LCMV and Pichinde virus
challenges
The main aim of the present study was to identify an
immunological mechanism that underlies the protection
induced by LV proteins, with a secondary goal of
determining if a vaccine comprising LV sequences could
induce cross-reactive immunity against both Old World and
New World arenaviruses. This laboratory (An and Whitton,
1997; Hassett et al., 2000a; Rodriguez et al., 1997, 1998,
2001; Yokoyama et al., 1995, 1996; Zhang et al., 2002)
and others (Pedroza Martins et al., 1995; Zarozinski et al.,
1995) have shown that DNA vaccines encoding LCMV
proteins can confer rapid and effective protection against
subsequent challenge with homologous virus, and these
data encouraged us to use DNA vaccines to evaluate the
protective immunity induced by LV proteins. As the first
step, a DNA vaccine encoding full-length LV NP (pLNP)
was generated and shown to express the LV protein
(Fig. 1). Next, this plasmid was tested for its ability to
protect against LCMV challenge in vivo. BALB/c and
C57BL/6 mice were immunized with one of three plasmid
DNAs: pCMV (negative control); pNP (encoding LCMV
NP); or pLNP (encoding LV NP). Three weeks later, the
mice were challenged with LCMV and, 4 days post-
infection, were sacrificed and LCMV titers in the spleen
were determined (Fig. 2, left panels). At this time point
post-infection, previously non-immune mice have high
virus titers; for example, BALB/c mice inoculated with the
negative control plasmid pCMV had ~4  106 pfu of
LCMV per gram of splenic tissue. In contrast, BALB/c
mice immunized with the positive control plasmid encod-
ing LCMV NP showed ~1000-fold reduction in virus titers,
as reported previously (Yokoyama et al., 1997). Mice
immunized with the Lassa NP DNA vaccine also showed
substantial immunity to LCMV challenge, exhibiting a
~100-fold reduction in LCMV titers. Lassa NP-induced
protection was observed in both of the mouse strains used.
These data are consistent with a prior observation thated with pCMV or with pLNP and 24 h later were stained as described in
t microscope.
Fig. 2. LV DNA vaccines can induce effective cross-protective responses against LCMV and Pichinde virus. BALB/c and C57BL/6 mice (4 mice per group)
were immunized with the indicated plasmid DNAs and 3 weeks later were challenged with 2  105 pfu of LCMV (left panels) or with 2  107 pfu of PV (right
panels). Four days post-challenge, spleens, lungs and livers were harvested, and virus titers were determined. Splenic titers are shown; the observed differences
in titer among the groups were similar in the lung and liver. The limit of detection for virus in tissue samples is ~200 pfu per gram.
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typhimurium, protected BALB/c mice against subsequent
LCMV challenge (Djavani et al., 2001); the data in the left
part of Fig. 2 extend that published work by showing that
(i) LNP also is effective when delivered via DNA
vaccination, and (ii) LNP protects both BALB/c and
C57BL/6 mice. In addition, we determined the protective
efficacy of the LCMV and Lassa NPs against a New World
arenavirus. The New World arenaviruses have been divided
into three phylogenetic classes, A, B and C (Bowen et al.,
1996). Most of the viruses in clade B are human pathogens,
and several (Guanarito, Junin, Machupo, Sabia) are
categorized as NIH risk group 4, and – like LV – can be
handled only under biosafety level 4 conditions (CDC and
NIH, 1999). These biosafety restrictions excluded such
viruses from the present study, and therefore as a
representative New World agent, we selected Pichinde
virus (PV; Trapido and Sanmartin, 1971). This virus, a
member of clade A, is classified as a biosafety level 2
agent and has been studied in a number of small animal
models including guinea pigs (Jahrling et al., 1981) and
hamsters (Gee et al., 1978; Ozols et al., 1994); most
importantly for the present study, there is a well-established
mouse model of infection (Selin et al., 1994; Walker et al.,
1984; Wright et al., 1995). The protective efficacy of Old
World arenavirus NPs against PV is shown (Fig. 2, right
panels). Substantial protection was observed in BALB/c
vaccinees, in which viral titers were reduced by ~100- to
1000-fold. In contrast, only ~5-fold reductions in titer were
observed in DNA-immunized C57BL/6 mice. Others have
reported that the NPs of LCMV and PV share at least one
cross-reactive CD8+ T cell epitope presented by the Kb
MHC class I allele (Brehm et al., 2002), and that LCMV-immune mice show some (5- to 13-fold) reduction in titer
following PV challenge (Selin et al., 1998). However,
although we saw a similar level of protection in DNA-
immunized C57BL/6 mice, statistical analyses of our data
indicated that this was unlikely to be significant. Therefore,
we limited our remaining studies to BALB/c mice.
The Lassa NP DNA vaccine induces virus-specific CD8+
T cells
These results, along with published data from guinea pig
studies, show that Lassa NP can induce protective
immunity against at least three arenaviruses: LV, LCMV
and Pichinde virus. This conclusion was not based solely
on splenic virus titers because, in both the LCMV- and PV-
challenged mice described above, virus titers also were
determined in lung and liver (data not shown); the patterns
of protection (or lack thereof) were indistinguishable from
those observed in the spleen. However, the underlying
mechanism of protection is unknown and could, in theory,
have resulted from the induction of either virus-specific
antibodies or T cells. As described in the Introduction, data
from LV challenge models implicate cellular immunity in
vaccine-mediated protection, but the evidence is circum-
stantial. Therefore, to begin to address this issue, we
evaluated the ability of the Lassa NP DNA vaccine to
induce CD8+ T cell responses, and also determined if Lassa-
specific CD8+ T cells could recognize the LCMV NP. DNA
vaccine-induced CD8+ T cell responses sometimes can be
detected directly ex vivo, but in our first analysis we chose
to infect the DNA-inoculated mice with LCMV, and to
evaluate CD8+ T cell responses at 4 days post-infection. At
this time point, CD8+ T cell responses in previously non-
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successfully immunized mice are greatly accelerated and are
readily detected. Furthermore, this approach provided
information about whether or not CD8+ T cells induced by
Lassa NP could recognize, and be amplified by, LCMV in
vivo. BALB/c mice were immunized with pCMV or pLNP.
We have previously shown that DNA immunization can
induce fully functional protective CD8+ T cells within 14
days of plasmid injection (Zhang et al., 2002), and that these
cells (or their progeny) remain at relatively stable levels for
the lifetime of the host (Hassett et al., 2000b). For this
reason we waited for 14 days before challenging the mice
with LCMV. Four days post-infection, splenocytes were
harvested and were incubated with stimulator cells that had
been transfected, 24 h previously, with either pCMV
(negative control), pNP (encoding LCMV NP) or pLNP
(encoding Lassa NP). Four days after LCMV infection of a
pCMV-inoculated mouse, the spleen contained CD8+ T cells
that could recognize stimulator cells transfected with either
the LCMV NP or the Lassa NP, indicating that LCMV-
specific CD8+ T cells can recognize the Lassa NP (Fig. 3,
upper row). More importantly, mice that had been immu-
nized with pLNP prior to LCMV infection (Fig. 3, lower
row) showed greatly enhanced responses against stimulator
cells that had been transfected with either Lassa or LCMV
NP. These data indicate that the Lassa NP DNA vaccine had
induced memory CD8+ T cells, and that these cells could
cross-react with LCMV because the cells (i) had expanded
in vivo in response to the 4-day LCMV infection and (ii)
could recognize the stimulator cells transfected with the
LCMV NP. Taken together, the data in Figs. 2 and 3 areFig. 3. pLNP immunization induces CD8+ T cells that can recognize LCMV and L
and 2 weeks later were infected with LCMV. Four days post-infection, mice were
cl7 cells) that had been transfected 24 h previously with the plasmids indicated abo
ICCS, as described in Materials and methods. The numbers in the upper right
responded to the stimulator cells by producing IFNg (i.e., that were specific forconsistent with the hypothesis that the Lassa NP DNA
vaccine protects against arenavirus infection via the
induction of cross-reactive CD8+ T cells. However, the
full-length Lassa NP used here, and in all other published
studies, also can induce antibody responses and CD4+ T cell
responses. Indeed, it is known that a Lassa-specific CD4+ T
cell line can bestow cross-protective immunity against
LCMV (La Posta et al., 1993). Therefore, to determine
whether or not Lassa-specific CD8+ T cells could protect
against LCMV and Pichinde virus, we set out to identify
CD8+ T cell epitopes within Lassa NP, with the goal of
constructing DNA vaccines that expressed single Lassa
CD8+ T cell epitopes. We have previously shown that a
variety of viral epitopes, when delivered by such bminigeneQ
vaccines, can induce protective CD8+ T cell responses
against viral and bacterial challenge (An and Whitton, 1999;
Whitton, 1994; Whitton et al., 1993). To identify candidate
Lassa CD8+ T cell epitopes that might confer cross-
protection against LCMV and Pichinde virus, we combined
three approaches: first, we aligned and compared the amino
acid sequences of the three viral NPs; second, we used a
computer-based algorithm to predict potential epitopes in
the Lassa NP; and third, we exploited our knowledge of
epitopes in LCMV.
Sequence homologies between Lassa NP, and related Old
World and New World arenaviruses
A phylogenetic tree was obtained using the Megalign
componentof theDNASTARsoftwarepackage,andtheamino
acid sequences of the three viral NPs were aligned using theV NPs. BALB/c mice were immunized as indicated to the left of each row
sacrificed, and splenocytes were incubated with syngeneic fibroblasts (Balb
ve each column. After a 6-h stimulation, the splenocytes were evaluated by
quadrants indicate the percentages of all CD8+ T cells in the sample that
the proteins encoded by the transfected plasmid).
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URL: http://www.bibiserv.techfak.uni-bielefeld.de/dialign/).
As expected, the phylogenetic tree of the three NPs
(Fig. 4A) shows that LV and LCMV proteins are closely
related, while the Pichinde NP lies on a separate branch.
Detailed sequence alignments are shown in Fig. 4B. In
regions with little similarity, the Dialign 2 program
designates residues as bunalignedQ and represents them
in lower case; there are only four short regions showing
substantial variability (~150–160; ~260–280; ~340–360;
and near the C-termini of the proteins). Most of theFig. 4. Sequence alignments of the nucleoproteins from Old World and New Wor
aligned using Dialign 2, as described in the text. (Panel A) The overall relationsh
amino-acid alignments. (Panel B) The aligned sequences are shown. Lower case r
Aligned residues that are common to Lassa and to one or both of the related viruse
enclosed by a solid red line, and the LV sequences that ranked 1–5 using the ep
dashed blue lines. More information about these and other known (LCMV) or poresidues are upper case, indicating extensive similarity
among the three proteins. However, to generate a cross-
reactive vaccine, it may be preferable to identify se-
quences that are identical rather than merely similar. To
highlight sequence identity among the three viral proteins,
the aligned sequences were color coded; when an LCMV
and/or Pichinde virus residue is identical to the adjacent
Lassa amino acid, the identical residues are shown in
green. The aligned sequences contain many identical
residues, but divergent (black) amino acids are inter-
spersed throughout.ld arenaviruses. The nucleoproteins of LCMV, LV and Pichinde virus were
ips between the sequences are shown in a phylogenetic tree, based on the
esidues are those designated by the computer algorithm as being unaligned.
s are shown in green. The dominant H-2d LCMVepitope in the viral NP is
itope prediction computer algorithm SYPEITHI (see text) are enclosed by
tential (Lassa, Pichinde) sequences is presented in Table 1.
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nucleoproteins of LV, Pichinde virus and LCMV
Next, a computer algorithm was used to predict potential
CD8+ T cell epitopes within the Lassa NP, with the intent of
identifying candidate Lassa sequences that were identical
among the three viral NPs. The Lassa NP sequence was
analyzed using the SYFPEITHI predictive algorithm (Ram-
mensee et al., 1999, URL: www.syfpeithi.de) for the Ld
MHC class I allele, which preferentially binds nonameric
peptides that contain proline or serine at position 2, and
phenylalanine, leucine or methionine at position 9 (Corr et
al., 1992). Approximately 500 potential epitopes were
returned. The five top-scoring potential Lassa NP epitopes
are enclosed in dashed blue boxes in Fig. 4B and are listed
in Table 1, along with their SYFPEITHI scores (SS).
Because these Lassa sequences are candidates for inducing
cross-reactive immunity, it was important to determine, for
each Lassa epitope, the SYFPEITHI scores for the
equivalent LCMV and Pichinde sequences; these are
included in Table 1. Some of the predicted Lassa epitopes
appear extremely unlikely to induce cross-reactive immune
responses; for example, the LCMV and PV sequences
equivalent to LNP406–414 have extremely low rankings,
because the residue at the second position of the sequence is
not appropriate for Ld binding. Conversely, the third-ranked
Lassa epitope (LNP312–320; LSGDGWPYI) also is highlyTable 1
Summary of candidate Lassa NP epitopes in BALB/c mice and their
equivalents in LCMV and Pichinde virus
The NPs of LV, LCMV and PV were analyzed using the SYFPEITHI
program, and the top five nonameric Ld-binding peptides predicted for LNP
are shown. The shaded boxes (#2 and #9) indicate the peptide residues that
bind to the MHC molecule. aR = ranking of each epitope in SYFPEITHI.
bSS = raw SYPEITHI score. cPosition of the first amino acid of the epitope,
in the viral NP.ranked in LCMV and PV, and thus appears a promising
candidate.
The dominant LCMV NP CD8+ T cell epitope sequences are
altered in Lassa and Pichinde viruses
The CD8+ T cell responses to LCMV have been
extensively studied, and epitopes have been characterized
in BALB/c mice (summarized by von Herrath and Whitton,
2000). Because these LCMV sequences are already known
to be highly immunogenic, we hoped that they might be
retained in Lassa and Pichinde viruses, in which case they
would be obvious candidates for a Lassa-virus-based DNA
minigene vaccine. In LCMV-infected BALB/c mice, the
overwhelming majority of CD8+ T cells are specific for the
sequence RPQASGVYM, lying at residues NP118–126 and
presented by the Ld MHC allele (Whitton et al., 1989); this
sequence is enclosed in a solid red box in Fig. 4B, and the
equivalent sequence from Lassa NP is present in Table 1, as
the fifth-ranked LNP epitope. However, the related Pichinde
sequence had an extremely low SYFPEITHI score, and
ranking, suggesting that it would not be effectively
presented by the Ld molecule; this is consistent with a
previous study showing that this PV peptide failed to bind to
Ld (Oldstone et al., 2001).
Evaluating CD8+ T cell responses against candidate Lassa
NP epitopes
Based on the above considerations, we excluded the
LNP406–414 epitope from further analysis and evaluated the
immunogenicity of the remaining four LNP epitope candi-
dates. BALB/c mice were immunized with pLNP plasmid
DNA, or with the negative control plasmid pCMV, and 14
days later received a booster vaccination with the same DNA.
Two weeks thereafter, the mice were infected with LCMV,
which will selectively amplify any vaccine-induced Lassa-
specific CD8+ T cells that can cross-react with LCMV, and 4
days after LCMV infection the CD8+ T cell responses to
Lassa and LCMV peptides were evaluated using ICCS. The
results are shown in Fig. 5. pLNP immunization primed
CD8+ T cells that recognized the Lassa NP118 epitope and
could cross-react with the equivalent LCMV peptide. Others
have shown that, in the converse experiment, CD8+ T cells
induced by the LCMV NP118 sequence could recognize the
peptide sequence from Lassa (Oldstone et al., 2001) and,
intuitively, onemight think that the reciprocal cross-reactivity
shown here (in which Lassa-induced cells recognize the
LCMVepitope) would be inevitable. However, this is not the
case; we have previously shown, for this very epitope, that
CD8+ T cells specific for similar but distinct sequences can
exhibit unidirectional (i.e., non-reciprocal) reactivity (Whit-
ton et al., 1989). BALB/c mice also mounted a detectable
response against the Lassa NP271–279 peptide, but no CD8
+ T
cells specific for the Lassa NP179–187 or NP312–320 epitopes
were identified. Thus, a high score using the SYFPEITHI
Fig. 5. Evaluation of CD8+ T cell responses to candidate sequences in Lassa NP. BALB/c mice were immunized as described in the text, with pCMV, or with
pLNP, as indicated. Two weeks later, the mice were infected with LCMV, and 4 days thereafter splenocytes were harvested, incubated for 6 h with the indicated
peptides and analyzed by ICCS. The number beside each oval indicates the percentage of all CD8+ T cells in the sample that responded to peptide by producing
IFNg. The results are representative of three separate experiments.
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This conclusion was further borne out by the results of
similar analyses using C57BL/6 mice (not shown); none of
five peptides representing the highest Db SYFPEITHI scores
was able to stimulate IFNg production by CD8+ T cells from
pLNP-immunized mice.
A minigene DNA vaccines encoding the Lassa NP118–126
epitope induces CD8+ T cell responses that can be detected
directly ex vivo
The foregoing data indicated that most of the Lassa
sequences that had been identified as potential epitopes
were unlikely candidates for inclusion in a Lassa-based
minigene DNA vaccine. We chose not to test the protective
efficacy of the Lassa NP271–279 epitope, because it has
almost no identity with the related LCMVor Pichinde virus
sequences (Table 1). Therefore, we limited our minigene
study to the LNP118–126 sequence (RPLSAGVYM). A
minigene encoding these nine LV amino acids was cloned
in-frame with ubiquitin, which substantially enhances the
immunogenicity of minigene products (Rodriguez et al.,
1998), and the capacity of this vaccine to prime CD8+ T
cells was evaluated. BALB/c mice received a single
injection of this plasmid DNA, and 14 days later their
CD8+ T cell responses were measured by ICCS directly ex
vivo; in this case, the vaccine-induced responses were not
amplified by LCMV infection. As shown in Fig. 6, ~1.9% of
CD8+ T cells from a vaccinated mouse responded to the
LNP118–126 peptide by producing IFNg, demonstrating that
a single inoculation of this Lassa minigene vaccine can
induce strong CD8+ T cell responses. To determine the
cross-reactivity of these minigene-induced LNP118-specific
cells, the splenocytes were stimulated with the LCMVNP118 peptide (Fig. 6, lower right panel). Some of the
LNP118 minigene-induced cells responded to the LCMV
peptide, confirming the observation that the full-length
LNP-induced CD8+ T cells that could cross-react with the
LCMV NP118 epitope (Fig. 5, lower right panel). The much
greater response to the LCMV peptide observed in Fig. 5 is
attributable to the 4-day LCMV infection that preceded the
analysis; this infection would result in the selective
expansion of the cross-reactive T cells. Such infection,
and expansion, did not take place prior to the analyses
reported in Fig. 6. Next, having shown that the Lassa
minigene vaccine induced cross-reactive CD8+ T cells
(albeit at low frequency), we determined whether or not
these cells could protect against LCMV challenge.
The Lassa NP118 minigene vaccine protects against
challenge with LCMV, but not Pichinde virus
BALB/c mice were immunized with the LNP118–126
minigene vaccine, or with plasmids encoding the full-length
Lassa or LCMV NPs, or with pCMV. To demonstrate the
MHC specificity of any protective effects of the LNP118–126
minigene, identical immunizations were administered to
C57BL/6 mice. Two weeks later, all mice were challenged
with LCMV, and 4 days following infection the spleens were
harvested and virus titers were determined. As shown in
Fig. 7, the LNP118–126 minigene conferred solid protection
upon BALB/c mice; the virus titers were similar to those
found in mice that had been vaccinated with full-length NP
from Lassa or LCMV. As a control for MHC specificity, this
minigene vaccine also was evaluated in C57BL/6 mice; as
expected, and in contrast to the full-length NP and LNP, no
protection was observed with this minigene vaccine. The
minigene immunization and challenge experiments in
Fig. 6. The Lassa NP118 minigene vaccine induces CD8+ T cells, some of which respond to LCMV peptide. BALB/c mice were inoculated once with the
indicated plasmid DNA and, 2 weeks later (without subsequent LCMV infection) the splenocytes were evaluated by ICCS for their responsiveness to the
indicated peptides. The number beside each oval indicates the percentage of all CD8+ T cells in the sample that responded to peptide by producing IFNg.
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times, and in all cases we observed (i) low numbers of
vaccine-induced cross-reactive CD8+ Tcells, when measured
prior to LCMV infection, that nevertheless conferred (ii)
strong protection against LCMV challenge. Taken together,
these data indicate that the protective effects of the LVNP can
be mediated by CD8+ T cells, and can induce cross-reactive
protection against challenge with a related Old World
arenavirus. As expected, given the very low ranking of the
equivalent sequence in PV (Table 1), the LNP118–126
minigene vaccine failed to protect BALB/c mice against
PV challenge (data not shown).Fig. 7. LV minigene vaccines: protection against LCMV challenge. BALB/c or C
indicated on the x-axis and 2 weeks later the mice were challenged with LCMV
harvested, and virus titers were determined. Splenic titers are shown; the observed
limit of detection for virus in tissue samples is ~200 pfu per gram.Discussion
The protective efficacy of any antiviral vaccine is
determined, in part, by the natural history of the related
virus; ideally, a vaccine should induce immune responses
that can exert their effector functions at, or near, the portal
of entry. For example, vaccines targeted towards a
respiratory pathogen such as influenza virus should induce
immunity in the upper and lower respiratory tract, while
primary immunity to poliovirus might best lie in the
gastrointestinal system. The route of transmission of LV
remains a matter of conjecture. Airborne person-to-person57BL/6 mice (4 mice per group) were immunized once with the plasmids
(2  105 pfu ip). Four days post-challenge, spleens, lungs and livers were
differences in titer among the groups were similar in the lung and liver. The
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suggesting that respiratory infection by the inhalation of
aerosolized materials is an infrequent event (Keenlyside et
al., 1983); the virus may, instead, enter the human host
through cuts or abrasions. Consistent with these observa-
tions, nosocomial transmission can be prevented by very
basic barrier nursing techniques (Cooper et al., 1982;
Fisher-Hoch et al., 1985). If, indeed, the major route of LV
transmission is by direct inoculation, then one might
predict that a vaccine that induced mucosal immunity
alone would confer only limited protection; and that
the induction of a strong systemic immune response
– including CD8+ T cells – would be advantageous. As
noted in the Introduction, others have demonstrated the
feasibility of immunization against Lassa fever in animal
models and have speculated that protection is conferred by
cellular immunity. However, other observations argue
against this conclusion. For example, a recombinant LNP
protected ~50% of animals against LV challenge (Ignat’ev,
2002); this is unlikely to have been mediated by CD8+ T
cells, which are induced poorly, if at all, by the injection of
soluble protein. Furthermore, beneficial effects have been
reported when convalescent plasma was administered early
in the acute disease (Frame et al., 1984), consistent with a
role for Lassa-specific antibodies, although subsequent
controlled studies did not confirm this finding (McCormick
et al., 1986). Here, we provide the first experimental data to
show that isolated LV CD8+ T cell epitopes can confer
protection against related arenaviruses, even in the absence
of vaccine-induced antibodies.
Both the Old World and New World groups of
arenaviruses harbor serious human pathogens. LCMV and
LV are members of the Old World viruses, while Guanarito,
Machupo, Sabia and Junin viruses lie in the New World
group. Our results (Fig. 2) indicate that a DNA vaccine
encoding LNP or LCMV NP can protect against members of
both groups, suggesting the possibility of a universal
arenaviral vaccine. However, such bpan-arenaviralQ protec-
tion was observed only in BALB/c mice, underscoring the
MHC-related susceptibility described above. The suscepti-
bility of LCMV NP-immunized C57BL/6 mice to PV
infection (Fig. 2, right panel) was surprising because the
NPs of LCMV and PV share at least one cross-reactive, and
possibly protective, CD8+ T cell epitope presented by the Kb
MHC class I allele (PV NP205–212, YTVKFPNM; LCMV
NP205–212, YTVKYPNL) (Brehm et al., 2002; Selin et al.,
1998). The equivalent LV sequence (LNP209–216, YTA-
KYPNT) is relatively well maintained but, despite this,
pLNP does not confer immunity against PV challenge in
C57BL/6 mice (Fig. 2).
Studies of LV vaccines in rodents (mice and guinea
pigs) and primates share at least two common features:
first, Lassa GP can confer protection against challenge
with LV, or other arenaviruses; and second, the induction
of antibodies by LV vaccines plays no detectable role in
conferring protection against subsequent virus challenge.The data reported herein extend the second point by
showing clearly that a Lassa vaccine that induces only
CD8+ T cells can protect against related arenaviruses.
However, there is one a marked discrepancy between the
rodent and primate results; in the former, Lassa NP
confers solid protection (this study, and others cited
above), while in the latter, Lassa NP fails to protect,
and may even be detrimental (Fisher-Hoch et al., 2000).
Intuitively, it seems reasonable to argue that primate
studies may better predict the outcome of human
vaccination and, in that case, a human vaccine against
LV would not require the NP, and possibly should
exclude it. However, a vaccine that contains only part
of a pathogen’s genome carries with it a well-recognized
risk; depending on their MHC haplotype (in the case of
CD8+ T cells, the MHC class I haplotype), individual
vaccinees may, or may not, respond to the vaccine. This
risk, which is substantial, is clearly demonstrated by the
data in Fig. 7; the Lassa NP118–126 minigene vaccine
protects BALB/c mice, which can present the epitope via
the Ld molecule, but not C57BL/6 mice, which lack this
MHC allele. Similar outcomes may be expected of any
epitope-based vaccine. This laboratory was the first to
show that CD8+ T cell epitope encoded by a minigene
could be presented for T cell recognition and to
demonstrate the potential of multi-epitope constructs
(which we named bstring of beadsQ vaccines; Whitton et
al., 1993). We designed this approach to circumvent the
limited coding capacity of then-current delivery systems
(e.g., recombinant vaccinia virus) for foreign antigens.
However, such space constraints do not apply to DNA
vaccines, which can be administered as a cocktail of
multiple plasmids, which together can encode an entire
microbial proteome (Barry et al., 1995). Consequently, the
benefits of epitope-based vaccination – which has been
widely duplicated by other laboratories, and variously re-
named multi-epitope, multivalent, or polytope vaccination
(Suhrbier, 1997; Thomson et al., 1995; Yu et al., 1998)
– seem to us questionable. Indeed, we consider it
desirable that a vaccine should include as much of the
pathogen’s proteome as is possible. As noted above, there
is overwhelming, and long-standing, evidence that arena-
virus NP (as well as GP) can confer strong CD8+ T cell-
mediated immunity against subsequent challenges. Taken
together, and despite the results in rhesus macaques, these
considerations suggest to us that DNA vaccines against
LV should encode as much of the proteome as possible,
including both Lassa NP and GP.Materials and methods
Virus and mice
Pichinde virus, and the Armstrong strain of LCMV,
were used. BALB/cByJ and C57BL/6 were obtained from
M.P. Rodriguez-Carreno et al. / Virology 335 (2005) 87–9896The Scripps Research Institute breeding facility. NaRve
mice or DNA-immunized mice (6–12 weeks of age) were
infected with LCMV [2  105 plaque forming units (pfu)
intraperitoneally (ip)] or with Pichinde virus [2  107
plaque forming units (pfu) intraperitoneally (ip)] and were
sacrificed at the indicated time points, for analysis of virus
titers, FCD8+ T cell responses. All animal experiments
were performed in compliance with the Institutional
Animal Care and Use Committee at The Scripps Research
Institute.
Virus titration
LCMV titers were determined by plaque assay on
Vero cell monolayers maintained in DMEM medium
supplemented with 10% FBS, 20 mM l-glutamine,
penicillin G (50 U/L) and streptomycin sulphate (50
Ag/L). Tissue samples were weighed and homogenized in
0.5 ml of OPTIMEM (Invitrogen, Carlsbad, CA). The
homogenates were serially diluted in OPTIMEM, and
these were used to infect Vero cells. After 1 h absorption
at 37 8C, the inoculum was removed and the cells were
overlaid with medium DMEM 0.25% FBS 0.25%
Seakem ME agarose (Cambrex, Rockland, ME). After 5
days of incubation at 37 8C, the monolayers were fixed
in 25% formaldehyde–PBS and stained with 0.05%
crystal violet in PBS containing 20% ethanol. The limit
of detection for virus in tissue samples is ~200 pfu
per gram.
DNA constructs and peptides
The plasmid encoding the LCMV NP and the negative
control plasmid pCMV have been described and charac-
terized previously (Yokoyama et al., 1995). The nucleo-
protein from LV (Josiah strain) was obtained from Dr. C.
Clegg and was cloned into pCMV (Clontech, Palo Alto,
CA). Expression of the LNP was confirmed by immuno-
fluorescence (Fig. 1) of transfected cells using a mono-
clonal antibody that cross reacts with the NP from several
arenaviruses (Buchmeier et al., 1981). Minigenes were
prepared using overlapping oligonucleotides and were
cloned into pCMV-Ub, a plasmid that encodes mouse
ubiquitin (Rodriguez et al., 1997, 1998); the resulting
minigene vaccine encodes a ubiquitin–epitope fusion
protein. Peptides representing the various LCMV epitopes
were purchased from PeptidoGenic Research and Co. Inc.,
(Livermore, CA) as HPLC-purified (N95% pure) material,
and stock solutions were prepared in water or 10% DMSO/
water.
DNA immunization
Plasmid DNA was prepared using Qiagen Megaprep
columns according to the manufacturer’s recommendations
and was washed with endotoxin removal buffer (40%ethanol, 5% acetic acid). A 28-gauge needle was used to
inject DNA (50 Ag DNA in 50 Al of 0.9% NaCl) into each
anterior tibialis muscle.
In vitro transfections and loading of stimulator cells with
peptide
Cells were transfected using the Lipofectamine PLUS
Reaction kit (Life Technologies Inc., Gaithersburg, MD)
according to the manufacturer’s recommendations. Cells
were incubated in OPTI-MEM I medium (Life Technologies
Inc., Gaithersburg, MD) for 3 h, after which complete
medium was added.
Transfection of tissue culture cells
To confirm expression of the LV nucleoprotein, 2 Ag of the
plasmid pLNP was transfected into HeLa cells at 60%–80%
confluence, using Lipofectamine, as described by the
manufacturer Invitrogen (Carlsbad, CA). For ICCS assays
(described below) that employed transfected stimulator cells,
Balb cl7 fibroblast cells were transfected with the indicated
plasmid, using the same reagents and conditions, and the
transfected cells were used in the ICCS assay 24 h later.
Intracellular cytokine staining (ICCS) and flow cytometry
Spleen cells from LCMV immune mice were cultured in
96 well U-bottom plates (2  106 cells per well) in complete
RPMI [RPMI with 5% fetal bovine serum (FBS), 20 mM
HEPES, 2 mM l-glutamine, 1 u/ml penicillin G and 100 Ag/
ml streptomycin], at 37 8C, 5% CO2 for 6 h, in the presence
of the indicated peptides (at final concentration of 106M).
Brefeldin A (5 Ag/ml; Sigma, St. Louis, MO) was present
throughout the incubation. At the indicated time points, cells
were harvested, washed with 2% FBS–PBS and stored on
ice. Cells were stained overnight at 4 8C with anti-CD8
antibody (clone CT-CD8a, Caltag, Burlingame, CA), washed
and fixed in PBS containing 2% formaldehyde. Following
fixation, the cells were permeabilized and stained for
cytokines according to the manufacturer’s directions (Phar-
Mingen, San Diego, CA). Samples were resuspended in PBS
containing 2% formaldehyde and acquired on a FACScan
flow cytometer (100,000–300,000 events acquired per
sample). Data were analyzed with CellQuest software
(Becton Dickinson, San Jose, CA). For each epitope-specific
CD8+ T cell population, the epitope-specific responses to
peptide stimulation were calculated by subtracting the
percent of cells that scored positive for IFNg production in
the absence of peptide.
Statistical analysis
Statistical significance was determined using Excel
software (Microsoft, Seattle, WA). A P value of V0.05
was considered statistically significant.
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